Top 5 Changes to AHFS Drug Information 2022: What You Need to Know
The American Hospital Formulary Service (AHFS) Drug Information is a comprehensive resource that provides healthcare professionals with accurate information on prescription medications. As new drugs are introduced and existing drugs are modified, AHFS Drug Information undergoes changes to ensure that the latest information is available to medical professionals. Here are the top 5 changes you need to know about in the 2022 edition of AHFS Drug Information.
1. Updated drug monographs
AHFS Drug Information contains detailed drug monographs that provide important information about dosage, administration, indications, and adverse effects. In the 2022 edition, drug monographs have been updated to reflect new clinical data and changes in drug labeling. For example, the monograph for insulin glargine now includes information on its use for pediatric patients, while the monograph for remdesivir has been updated to reflect its approval for the treatment of COVID-19.
2. New drug monographs
As new drugs are approved for use, they are added to AHFS Drug Information. The 2022 edition includes new drug monographs for several recently approved medications, including Zosyn (piperacillin/tazobactam), Orladeyo (berotralstat), and Evkeeza (lumbrokinase).
3. Expanded information on biosimilars
Biosimilars are complex drugs that are highly similar to a reference biologic product. The 2022 edition of AHFS Drug Information includes expanded information on biosimilars, including a new section on the interchangeability of biosimilars with reference biologic products. This information can help healthcare professionals make informed decisions about the use of biosimilars in clinical practice.
4. Updated drug interactions
AHFS Drug Information provides detailed information on drug interactions, which can help healthcare professionals avoid potentially harmful combinations of medications. In the 2022 edition, the section on drug interactions has been updated to reflect new data on potential interactions between drugs. For example, the interaction between remdesivir and chloroquine/hydroxychloroquine is now listed as a potentially serious interaction.
5. Improved search functionality
AHFS Drug Information is a large resource with a wealth of information. To make it easier for healthcare professionals to find the information they need, the 2022 edition has improved search functionality. The search function now includes a predictive search feature that suggests relevant topics as the user types in the search box. This can save time and make it easier to find the information you need quickly.
Conclusion
AHFS Drug Information is an invaluable resource for healthcare professionals who need accurate and up-to-date information on prescription medications. The 2022 edition includes several important changes, including updated drug monographs, new drug monographs, expanded information on biosimilars, updated drug interactions, and improved search functionality. By staying up-to-date with these changes, healthcare professionals can provide the best possible care to their patients.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)